Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
Open Access
- 21 January 2021
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (5), 1244-1253
- https://doi.org/10.3324/haematol.2020.262691
Abstract
Activation of JAK-STAT signaling is one of the hallmarks of myelofibrosis, a myeloproliferative neoplasm that leads to inflammation, progressive bone marrow failure, and a risk of leukemic transformation. Around 90% of patients with myelofibrosis have a mutation in JAK2, MPL, or CALR: so-called ‘driver’ mutations that lead to activation of JAK2. Ruxolitinib, and other JAK2 inhibitors in clinical use, provide clinical benefit but do not have a major impact on the abnormal hematopoietic clone. This phenomenon is termed ‘persistence’, in contrast to usual patterns of resistance. Multiple groups have shown that type 1 inhibitors of JAK2, which bind the active conformation of the enzyme, lead to JAK2 becoming resistant to degradation with consequent accumulation of phospho-JAK2. In turn, this can lead to exacerbation of inflammatory manifestations when the JAK inhibitor is discontinued, and it may also contribute to disease persistence. The ways in which JAK2 V617F and CALR mutations lead to activation of JAK-STAT signaling are incompletely understood. We summarize what is known about pathological JAK-STAT activation in myelofibrosis and how this might lead to future novel therapies for myelofibrosis with greater disease-modifying potential.Keywords
This publication has 116 references indexed in Scilit:
- Regulation of Janus kinases by SOCS proteinsBiochemical Society Transactions, 2013
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013
- Age-related differences in disease characteristics and clinical outcomes in polycythemia veraLeukemia & Lymphoma, 2013
- JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneBlood, 2012
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With MyelofibrosisMayo Clinic Proceedings, 2011
- Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2Genes & Cancer, 2011
- Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid LeukemiaClinical Cancer Research, 2010
- Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1Molecular and Cellular Biology, 2009
- RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemiaPublished by American Society of Hematology ,2009
- Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdensExperimental Hematology, 2008